Mood disorders - Articles - Page 7

CARLAT WEBINAR

Treatment of Depression During Pregnancy

September 13, 2022

0.50 CME Credits. How to have a discussion with patients and to document risks and benefits to educate them the baseline risk of depression treatment in pregnancy.

SAINT TMS Cleared for Treatment-Resistant Depression

September 12, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

On 9/6/22 the FDA approved Stanford’s SAINT Neuromodulation, an accelerated version of TMS that has raised hopes with unusually high remission rates.

CLINICAL UPDATE

Six Tips From Prescribing Psychotropics

August 1, 2022

Chris Aiken, MD

Chris Aiken, MD.

Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.

RESEARCH UPDATE

Antidepressants for Suicidal Ideation in Depressed Patients?

July 1, 2022

James Black, MD

James Black, MD. Dr. Black has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antidepressants reduce suicidality even among patients who remain depressed.

A New Option for Bipolar Depression

January 24, 2022

Lumateperone (Caplyta) just got FDA approved for bipolar depression. Find out how it compares to other atypical antipsychotics.

CLINICAL UPDATE

Six Tips for Working With Older Adults

March 26, 2021

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Rehan Aziz, MD, explains how to interview older adults and which medications to use and which ones to avoid in this population.

RESEARCH UPDATE

Beta Blockers and Depression: The Controversy Revisited

November 12, 2020

Sean Ransom, PhD, MP.

Sean Ransom, PhD, MP. Dr. Ransom has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antihypertensives are among the world’s most widely prescribed drugs, but many of them impact pathways associated with depression. Beta blockers have long been believed to cause depression, but most of these studies were carried out decades ago and their findings have been inconsistent.

CLINICAL Q&A

The Modafinils in Bipolar Depression

June 10, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Provigil and Nuvigil, the modafinils, may not work for full depressive episodes, but they do something else in bipolar disorder that’s important to patients. This article explores their cognitive effects, as well as their potential to cause addiction and mania.

EXPERT Q&A

Inflammatory Biomarkers in Depression

February 10, 2020

Andrew H. Miller, MD

Andrew H. Miller, MD

William P. Timmie Professor of Psychiatry and Behavioral Sciences, Emory University, GA Dr. Miller has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Andrew Miller, Vice Chair of Psychiatry Research at Emory University, translates two decades research on inflammation and depression into practical terms, including a low-cost biomarker that may guide antidepressant selection.